899418-65-6
Chemical Structure
SAR113945 monopotassium
- CAS No.: 899418-65-6
- Formula:C28H24KN7O3
- Molecular Weight:545.63
IUPAC Name: potassium (S)-2-(2-(2-(methylamino)pyrimidin-4-yl)-1H-indole-5-carboxamido)-3-(phenyl(pyridin-2-yl)amino)propanoate
InChIKey: ZPPPVORWVAWUEJ-JIDHJSLPSA-M
SMILES: O=C(O[K])[C@H](CN(C1=CC=CC=C1)C2=NC=CC=C2)NC(C3=CC4=C(NC(C5=NC(NC)=NC=C5)=C4)C=C3)=O
Biological Activity: SAR113945 monopotassium is a highly selective IKK-β inhibitor with an IC50 value of 0.4 nM. SAR113945 monopotassium blocks the canonical NFκB signaling pathway. SAR113945 monopotassium alleviates hyperalgesia to heat and mechanical stimuli, and exerts effects in a zymosan-induced knee joint inflammation model. SAR113945 monopotassium is applicable to research related to symptomatic knee osteoarthritis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SAR113945 monopotassium | SAR113945 monopotassium is a highly selective IKK-β inhibitor with an IC50 value of 0.4 nM. SAR113945 monopotassium blocks the canonical NFκB signaling pathway. SAR113945 monopotassium alleviates hyperalgesia to heat and mechanical stimuli, and exerts effects in a zymosan-induced knee joint inflammation model. SAR113945 monopotassium is applicable to research related to symptomatic knee osteoarthritis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Grothe K, et al. IκB kinase inhibition as a potential treatment of osteoarthritis - results of a clinical proof-of-concept study. Osteoarthritis Cartilage. 2017 Jan;25(1):46-52. [Content Brief]
- [2]. Liu D, et al. Small molecule inhibitors of osteoarthritis: Current development and future perspective. Frontiers in physiology. 2023;14:1156913. [Content Brief]
- [3]. Noha SM, et al. Discovery of a novel IKK-β inhibitor by ligand-based virtual screening techniques. Bioorganic & medicinal chemistry letters. 2011 Jan 01;21(1):577-83. [Content Brief]
